Adam

@immad @mercury dashboarding - have some ideas. I’d do it myself but not a dev. - would take 10x time. Would love to discuss.

What would be good user-facing gen AI applications you can think of for @Mercury? The most compelling ones we have thought of are all behind the scenes.

@billionclubnft @wilfriedchung

🚨1 ETH Giveaway on the @billionclubnft 🚨 To celebrate the final hours of fusion, we are giving away 1 ETH! 🎁 To enter: 1️⃣ Like and Retweet 2️⃣ Follow us 3️⃣ Tag a friend on this post (each comment is an extra entry😉) #NFT #NFTGiveway #BCfusionevent #Ethereum

@dhovekamp42 @InTheTrenches2 @PersimmonTI @JacobPlieth @themotleyfool Appreciate this article but the value of their collab with Genentech is worth $3B by itself. Even if you want to discount that to today, prob $1B. $ADAP board not going to accept a $3B deal and Genentech not going to let it go for that if they already bought in for $3B

@InTheTrenches2 @PersimmonTI That would complete Jacobs @JacobPlieth $RHHBY $NVS oil soap analogy - combined with the @themotleyfool $PFE buyout fantasies on $ADAP and $AFMD and so it could get a hot block buster bidding war story fool.com/investing/2021…

$AFMD Would be poetic if $NVS repaid $RHHBY for unrequited love by purloining multi-Roche partnered $AFMD with its newfound billions…

@reilly_mcadams AMZN, AAPL

I hear people say “oh my dad had $AMZN at $18” or “my mother had $AAPL at $20 (pre split)” What do you guys think is going to be that stock our kids will be pissed we sold at these prices? Drop the ticker 👇

@10thbody10thbo1 @BertrandBio The press release does state Cohort 3 and expansion only. N=4 from July 2020 data cutoff in slide (1CR, 1SD, 2PD). New data from 10 months later (4/5/21) for Cohort 3 = 1CR, 4PD, xSD? =>> X=6SD. So, +5SD with 64% DCR.

$ADAP ILCA ADP-A2AFP update: apparently 2 new PD. n=11 evaluable, 1 CR already reported, 6 SD incl. 2 >16wks, 4 PD (vs 2 PD in n=9 evaluable) TRSAEs: 1 Gr1 CRS / 1 Gr2 IRR / 1 Gr3 febrile neutropenia

@HassanAesthetic @AIMInvestor4 @NatHarooni Best option is to be long across selective names. Do like $BEAM and $CRBU best purely from tech or access to tech licenses. Grabbing prime, base and/or license shares where I can.

@HassanAesthetic @AIMInvestor4 @NatHarooni Although base editing is awesome, they would need to pay ~$10-$12B to buy $BEAM. That may be too rich for them. $CRBU better option to get exposure and licenses to everything else.

@zachcoelius @garrytan It’s significant that SF moderates and liberals are so fed up that a recall is their only option

@garrytan You and your fellow super hero’s are our only hope.

I wonder if we will look back on the era of 2005-2020 SF as a golden era now gone forever. So many smart people gathered in one place building amazing things. Eventually destroyed by stupid ideology like so many renaissance periods of the past.

@srqstockpicker Lily $125M cash in $RIGL with RIP inhibitor along with +$800M bio bucks but just so happens $RIGL also has a IRAK1/4

Lil company going after irak4 in cancer

@SteelyRivers I was wrong ->>

The reverse split in $PHIO of 55-1 last year destroyed the warrants exp 12/2021. The SEC filing says exercise price adjust to 495.00. Read all warrant documents. Very, very important.

@avidresearch Not if you use current covid at home internet instruction as use case

This needs an intervention. Assuming “internet” will solve this soon.

@TheKendallBaker @biotechinvstr Pretty amazing. Throw in some trees and water and good-to-go.

Here's some footage (with sound!) from the surface of another planet, and you're just gonna scroll past it without even noticing to continue looking at memes, aren't you

@RNAiAnalyst Confused on the wnts. Agree latest offering has them already ITM ($3.00 strike) or close (~$3.87) and 5.5 year exp. But there are outstand ~$9 strike too. Ppl saying 12/31/21 exp. and ~$490ish strike (incorrect?). Which ones are PHIOW? Been buying <$0.75. Thks if u know.

$PHIO after offering, ~14M shares (incl from warrants in-the-money + near-the-money) --> market cap ~$56M Cash: ~$30M sec.gov/Archives/edgar… Attractive setup IMO, esp w/ upcoming clinical milestones + apparent investor/trader interest (--> volume 🚀).

@SteelyRivers Additionally, I believe “common warrants” (PHIOW) as of this latest offering has $3 exercise price and a 5 1/2 year expiration.

@SteelyRivers No, latest offering shows exercise of $3 and ~ $3.85